The quest for the Grail is beset with challenges.
In terms of private investments, 2020 was the year of the liquid biopsy.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.